Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)

Journal of Clinical Oncology

Volumn 32, Issue 11, 2014, Pages 1143-1150

  Smith, Matthew R ^a   Halabi, Susan ^b   Ryan, Charles J ^c   Hussain, Arif ^f   Vogelzang, Nicholas ^g   Stadler, Walter ^d   Hauke, Ralph J ^h   Monk, J Paul ⁱ   Saylor, Philip ^a   Bhoopalam, Nirmala ^e   Saad, Fred ^l   Sanford, Ben ^b   Kelly, W Kevin ^j   Morris, Michael ^k   Small, Eric J ^c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

^g Nevada Cancer Research Institute   (United States)

^h UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j THOMAS JEFFERSON UNIVERSITY   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CREATININE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LACTATE DEHYDROGENASE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ARTICLE; BONE METASTASIS; BONE NECROSIS; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FRACTURE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORCHIECTOMY; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; SPINAL CORD COMPRESSION; ADENOCARCINOMA; BONE TUMOR; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE COURSE; METASTASIS; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIAGNOSTIC IMAGING; DIPHOSPHONATES; DISEASE PROGRESSION; HUMANS; IMIDAZOLES; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84901944163     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.6500     Document Type: Article

References (17)

1. Gralow JR, Biermann JS, Farooki A, et al: NCCN task force report: Bone health in cancer care. J Natl Compr Canc Netw 3:S1-S32, 2009 (suppl 7)
2. Saylor PJ, Lee RJ, Smith MR: Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol 29:3705-3714, 2011
3. Brown JE, Cook RJ, Major P, et al: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69, 2005
4. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002
5. Saad F, Gleason DM, Murray R, et al: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882, 2004 (Pubitemid 38807610)
6. Zometa (zoledronic acid) Injection [package insert]. East Hanover, NJ, Novartis Pharmaceutical Corporation, 2012
7. Hussain M, Tangen CM, Berry DL, et al: Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-1325, 2013
8. Dearnaley DP, Sydes MR, Mason MD, et al: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 95:1300-1311, 2003 (Pubitemid 37160863)
9. Dearnaley DP, Mason MD, Parmar MK, et al: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10:872-876, 2009
10. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
11. Smith MR, Cook RJ, Coleman R, et al: Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 70:315-319, 2007 (Pubitemid 47362256)
12. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
13. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
14. Fizazi K, Carducci M, Smith M, et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377:813-822, 2011
15. Michaelson MD, Kaufman DS, Lee H, et al: Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038-1042, 2007 (Pubitemid 46596753)
16. Greenspan SL, Nelson JB, Trump DL, et al: Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial. Ann Intern Med 146:416-424, 2007 (Pubitemid 351650576)
17. Smith MR, Egerdie B, Hernández Toriz N, et al: Denosumab in men receiving androgendeprivation therapy for prostate cancer. N Engl J Med 361:745-755, 2009